Stock search

Ticker or company name

Edwards Lifesciences

EW · NYSE · Health Care

$107,11Down −0,04 (−0,04%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$61,6 bn
Div. yield
—
Year to date
+25,7%
52 weeks: $74,66$107,69

Ratio score

56/100
Ratio would watch

based on 9 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

5 ✓ · 0 — · 4 ✕ · 1 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM60,336,025,1
Forward P/E35,5—16,2
PEGn/a—2,2
P/S9,28,12,2
EV/EBITDA43,830,017,3
P/FCF42,6—19,5
P/B5,76,63,4

Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 39 analysts

Buy
32
Hold
7
Sell
0

Beat the EPS forecast in 3 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20260,760,80Up +5,4%
Q2 20260,760,78Up +2,3%
Q1 20260,750,78Up +4,2%
Q4 20250,640,58Down −8,8%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue1,72 bn1,74 bn1,65 bn1,57 bn1,55 bn1,53 bn1,41 bn1,39 bn1,35 bn1,39 bn1,60 bn1,27 bn
EPS0,530,420,660,160,500,560,610,655,130,610,580,61
Margin17,6%13,9%23,1%5,8%18,7%21,6%25,2%27,7%226,6%26,3%22,0%29,2%
FCF507 m585 m−21,1 m354 m516 m241 m224 m−177 m300 m286 m−119 m48,3 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $34,0 m.

NameAmountSharesPrice
lippis daniel j.10 Nov 2026 · sale$64 531619$104,25
zovighian bernard j9 Nov 2026 · sale$1,43 m13 916$102,78
zovighian bernard j9 Nov 2026 · sale$949 4899 184$103,39
bobo donald e jr9 Nov 2026 · sale$5,04 m48 900$103,05
lippis daniel j.8 Oct 2026 · sale$53 017619$85,65
lippis daniel j.11 Sep 2026 · sale$54 169619$87,51
dahl andrew m.31 Aug 2026 · sale$49 534544$91,06
bruls annette28 Aug 2026 · sale$237 9072 644$89,98
chopra daveen26 Aug 2026 · sale$2,79 m30 646$90,99
chopra daveen26 Aug 2026 · sale$105 8931 154$91,76
markowitz wayne26 Aug 2026 · sale$113 4171 240$91,47
lippis daniel j.11 Aug 2026 · sale$56 967619$92,03
markowitz wayne30 Jul 2026 · sale$12 561146$86,03
markowitz wayne28 Jul 2026 · sale$818 9589 628$85,06
zovighian bernard j27 Jul 2026 · sale$245 1722 921$83,93

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Health Care
Exchange
NYSE
Country
US
IPO date
27 Mar 2000

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
BDXBecton Dickinson$216,4738would not consider51,8−2,6%4,5%
BSXBoston Scientific$43,6983would consider18,4+8,9%16,6%
CAHCardinal Health$283,85no score35,7——
IDXXIdexx Laboratories$700,6583would consider47,2+11,9%25,4%
CORCencora$356,9483would consider19,7+5,1%0,8%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.